[go: up one dir, main page]

ZA200700537B - Benzyloxy derivatives at MAOB inhibitors - Google Patents

Benzyloxy derivatives at MAOB inhibitors

Info

Publication number
ZA200700537B
ZA200700537B ZA200700537A ZA200700537A ZA200700537B ZA 200700537 B ZA200700537 B ZA 200700537B ZA 200700537 A ZA200700537 A ZA 200700537A ZA 200700537 A ZA200700537 A ZA 200700537A ZA 200700537 B ZA200700537 B ZA 200700537B
Authority
ZA
South Africa
Prior art keywords
maob inhibitors
benzyloxy derivatives
benzyloxy
derivatives
maob
Prior art date
Application number
ZA200700537A
Other languages
English (en)
Inventor
Rodriguez-Sarmiento Rosa Maria
Wostl Wolfgang
Wyler Rene
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of ZA200700537B publication Critical patent/ZA200700537B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
ZA200700537A 2004-08-02 2007-01-18 Benzyloxy derivatives at MAOB inhibitors ZA200700537B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04103710 2004-08-02

Publications (1)

Publication Number Publication Date
ZA200700537B true ZA200700537B (en) 2008-05-28

Family

ID=35456889

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200700537A ZA200700537B (en) 2004-08-02 2007-01-18 Benzyloxy derivatives at MAOB inhibitors

Country Status (16)

Country Link
US (1) US7456210B2 (xx)
EP (1) EP1776337A2 (xx)
JP (1) JP4629105B2 (xx)
CN (1) CN100560566C (xx)
AR (1) AR050193A1 (xx)
AU (1) AU2005268894B2 (xx)
BR (1) BRPI0514077A (xx)
CA (1) CA2575018A1 (xx)
IL (1) IL180791A0 (xx)
MX (1) MX2007001169A (xx)
NO (1) NO20070972L (xx)
NZ (1) NZ552649A (xx)
RU (1) RU2378270C2 (xx)
TW (1) TWI291349B (xx)
WO (1) WO2006013049A2 (xx)
ZA (1) ZA200700537B (xx)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7501528B2 (en) * 2005-03-15 2009-03-10 Hoffmann-La Roche Inc. Method for preparing enantiomerically pure 4-pyrrolidino phenylbenzyl ether derivatives
KR101220182B1 (ko) * 2009-02-25 2013-01-11 에스케이바이오팜 주식회사 치환된 아졸 유도체 화합물, 이를 포함하는 약제학적 조성물 및 이를 이용한 파킨슨씨 병 치료방법
EP3087067B1 (en) * 2013-12-26 2018-10-24 Takeda Pharmaceutical Company Limited 4-(piperrazin-1-yl)-pyrrolidin-2-one compounds as monoacylglycerol lipase (magl) inhibitors
CN110240557B (zh) * 2018-03-08 2023-05-09 广东东阳光药业有限公司 吡咯烷酰胺衍生物及其用途
CN117088862B (zh) * 2023-08-22 2025-09-12 南华大学 一种硫代色元酮衍生物和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2500450A1 (fr) * 1981-02-25 1982-08-27 Delalande Sa Nouveaux derives aminomethyl-5 oxazolidiniques, leur procede de preparation et leur application en therapeutique
US5328920A (en) * 1991-04-17 1994-07-12 Hoechst-Roussel Pharmaceuticals Incorporated Substituted (pyridinylamino)-indoles
HU221138B1 (en) * 1994-08-30 2002-08-28 Sankyo Co Condensed isoxazolyloxy- and -thioalkylamine derivatives, process for the preparation thereof and pharmaceutical compositions containing them
US5679715A (en) 1995-06-07 1997-10-21 Harris; Richard Y. Method for treating multiple sclerosis
CA2244253C (en) 1996-03-15 2002-11-12 Somerset Pharmaceuticals, Inc. Method for preventing and treating peripheral neuropathy by administering selegiline
WO2001034172A2 (en) 1999-11-05 2001-05-17 Vela Pharmaceuticals Inc. Methods and compositions for treating reward deficiency syndrome
PE20050077A1 (es) * 2002-09-20 2005-03-01 Hoffmann La Roche Derivados de 4-pirrolidino-fenil-bencil-eter

Also Published As

Publication number Publication date
JP4629105B2 (ja) 2011-02-09
IL180791A0 (en) 2007-06-03
HK1108432A1 (zh) 2008-05-09
CN1993319A (zh) 2007-07-04
CN100560566C (zh) 2009-11-18
RU2378270C2 (ru) 2010-01-10
RU2007103236A (ru) 2008-09-10
US7456210B2 (en) 2008-11-25
AU2005268894B2 (en) 2010-12-16
NZ552649A (en) 2010-05-28
NO20070972L (no) 2007-02-28
TWI291349B (en) 2007-12-21
US20060025599A1 (en) 2006-02-02
JP2008508335A (ja) 2008-03-21
AU2005268894A1 (en) 2006-02-09
WO2006013049A3 (en) 2006-06-22
TW200612912A (en) 2006-05-01
MX2007001169A (es) 2007-03-12
EP1776337A2 (en) 2007-04-25
CA2575018A1 (en) 2006-02-09
BRPI0514077A (pt) 2008-05-27
AR050193A1 (es) 2006-10-04
WO2006013049A2 (en) 2006-02-09

Similar Documents

Publication Publication Date Title
IL179398A0 (en) Dpp-ib inhibitors
ZA200702394B (en) Indozolone derivatives as 11b-HSD1 inhibitors
ZA200700181B (en) Aryl-pyridine derivatives as 11-beta-HSD1 inhibitors
IL211894A0 (en) Amide derivatives
ZA200610771B (en) Quinazolinedolone derivatives as PARP inhibitors
ZA200805608B (en) Fungicide n-cycloalkyl benzyl amide derivatives
IL183657A0 (en) Amide derivatives
IL200842A0 (en) Pyrrole daao inhibitors
IL178125A0 (en) Gsk-3 inhibitors
ZA200501137B (en) Pyrrolidone derivatives as MAOB inhibitors
AP2321A (en) Quinoline derivatives for use as mycobactrial inhibitor.
IL189112A0 (en) NOVEL HETEROCYCLIC NF-kB INHIBITORS
GB0400290D0 (en) dUTPase inhibitors
PL1763517T3 (pl) Pochodne pirymidyny jako inhibitory 11BETA-HSD1
IL179305A0 (en) Dpp-iv inhibitors
ZA200700537B (en) Benzyloxy derivatives at MAOB inhibitors
GB0421355D0 (en) Inhibitors
EP1816194A4 (en) CANCER-SPECIFIC PROLIFERATION INHIBITORS
GB0421356D0 (en) Inhibitors
ZA200705150B (en) Amide derivatives
GB0516967D0 (en) Inhibitors
GB0408300D0 (en) Novel inhibitors
GB0409804D0 (en) Amide derivatives
GB0409800D0 (en) Amide derivatives
GB0427169D0 (en) Cathepsin S inhibitors